Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL)
The objective of the present study is to assess the value of mistletoe extract as a complement to standard treatment (palliative chemotherapy or best supportive care) in advanced pancreatic cancer patients with regard to overall survival and health-related quality of life.MethodsThe trial is prospective, randomised, double-blind, multicentre, parallel group and placebo-controlled. In total, 290 participants are randomly assigned to placebo or mistletoe extract given subcutaneously in increasing dosage from 0.01 to 20 mg three times per week for 9 months. Stratification is performed for site and palliative chemotherapy....
Source: Trials - September 10, 2020 Category: Research Source Type: clinical trials
Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Condition: Solid Tumor Intervention: Drug: Helixor® M Sponsor: Sidney Kimmel Comprehensive Cancer Center Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2017 Category: Research Source Type: clinical trials
